Clinical trial
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of…
NCT00022893 · Corixa Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00022893 |
|---|---|
| Title | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma |
| Official title | Retreatment Study of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti-B1 Antibody. |
| Lead sponsor | Corixa Corporation, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Iodine-131 Anti-B1 Antibody |
| First posted | Aug 17, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: